Pinto Joshua — SEC Form 4 filings
SEC reporting owner CIK 1992595. 13 Form 4 filings on record with FilingPulse; latest filed 2026-08-21.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2024-02-16 to 2026-08-21. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 4 filings — 114,015 shares, $1,197,438 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 41.
- Largest priced transaction: sale of 31,642 shares @ $11.78 ($372,588) in Neumora Therapeutics, Inc., filed 2024-08-26.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | President & CEO, Director | 11 | — | 6 legs · 114,015 sh · $1,197,438 | 34 |
| Metsera, Inc. (MTSR) | Director | 2 | — | — | 7 |
Form 4 filings — Pinto Joshua
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-21 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Neumora Therapeutics, Inc. (NMRA) | Sale (S): 5,967 @ $3.54 | EDGAR |
| 2026-01-09 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 1,200,000 (derivative) @ $0 | EDGAR |
| 2025-11-13 | 4 | Metsera, Inc. (MTSR) | Disposition to issuer (D): 2,688 · Grant/award (A): 2,688 (derivative) · Disposition to issuer (D): 16,125 (derivative) · Disposition to issuer (D): 148,953 (derivative) | EDGAR |
| 2025-05-30 | 4 | Neumora Therapeutics, Inc. (NMRA) | Disposition to issuer (D): 223,034 (derivative) · Disposition to issuer (D): 270,828 (derivative) · Disposition to issuer (D): 223,034 (derivative) · Disposition to issuer (D): 720,084 (derivative) · Disposition to issuer (D): 127,448 (derivative) · Disposition to issuer (D): 170,000 (derivative) · +8 more | EDGAR |
| 2025-05-23 | 4 | Neumora Therapeutics, Inc. (NMRA) | Gift (G): 13,202 @ $0 · Gift (G): 13,202 @ $0 | EDGAR |
| 2025-05-22 | 4 | Metsera, Inc. (MTSR) | Grant/award (A): 16,125 (derivative) @ $0 · Gift (G): 148,953 (derivative) @ $0 · Gift (G): 148,953 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Neumora Therapeutics, Inc. (NMRA) | Sale (S): 8,048 @ $1.67 | EDGAR |
| 2025-02-18 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 3,000,000 (derivative) @ $0 · Disposition to issuer (D): 223,034 (derivative) · Disposition to issuer (D): 270,828 (derivative) · Disposition to issuer (D): 223,034 (derivative) · Disposition to issuer (D): 720,084 (derivative) · Disposition to issuer (D): 127,448 (derivative) · +7 more | EDGAR |
| 2024-08-27 | 4 | Neumora Therapeutics, Inc. (NMRA) | Sale (S): 15,693 @ $11.39 | EDGAR |
| 2024-08-26 | 4 | Neumora Therapeutics, Inc. (NMRA) | Sale (S): 28,496 @ $11.63 · Sale (S): 24,169 @ $11.59 · Sale (S): 31,642 @ $11.78 | EDGAR |
| 2024-06-28 | 4 | Neumora Therapeutics, Inc. (NMRA) | Gift (G): 238,965 @ $0 | EDGAR |
| 2024-02-16 | 4 | Neumora Therapeutics, Inc. (NMRA) | Grant/award (A): 85,000 @ $0 · Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1992595 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →